Johnson & Johnson (JNJ): Price and Financial Metrics
Johnson & Johnson (JNJ)
Today's Latest Price: $143.27 USD
Updated Jul 8 4:10pm
Add JNJ to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 213 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
JNJ Stock Summary
- With a market capitalization of $376,694,326,614, Johnson & Johnson has a greater market value than 99.82% of US stocks.
- Johnson & Johnson's stock had its IPO on January 1, 1986, making it an older stock than 92.91% of US equities in our set.
- The volatility of Johnson & Johnson's share price is greater than that of merely 1.17% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to JNJ, based on their financial statements, market capitalization, and price volatility, are WMT, V, TSM, BRK.B, and MA.
- Visit JNJ's SEC page to see the company's official filings. To visit the company's web site, go to www.jnj.com.
JNJ Stock Price Chart Technical Analysis Charts
JNJ Price/Volume Stats
| Current price | $143.27 | 52-week high | $157.00 |
| Prev. close | $142.85 | 52-week low | $109.16 |
| Day low | $141.70 | Volume | 6,257,537 |
| Day high | $143.39 | Avg. volume | 9,442,926 |
| 50-day MA | $145.59 | Dividend yield | 2.83% |
| 200-day MA | $140.75 | Market Cap | 377.46B |
Johnson & Johnson (JNJ) Company Bio
Johnson & Johnson researches and develops, manufactures, and sells various products in the health-care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. Some of its well-known brands include Tylenol-fever, Listerine-bad breath, Splenda-no-calorie sweetener, Neutrogena-skin care, Pepcid-heartburn, Zyrtec - allergy, Motrin-ibuprofen, Sudafed-allergy, and plenty more. The company was founded in 1885 and is based in New Brunswick, New Jersey.
JNJ Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $143.27 | $82.75 | -42% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Johnson & Johnson. To summarize, we found that Johnson & Johnson ranked in the 35th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 41.83%. As for the metrics that stood out in our discounted cash flow analysis of Johnson & Johnson, consider:
- As a business, JNJ is generating more cash flow than 97.96% of positive cash flow stocks in the Healthcare.
- The business' balance sheet reveals debt to be 7% of the company's capital (with equity being the remaining amount). Approximately just 17.18% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- JNJ's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 44.76% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -43% |
| 1% | -43% |
| 2% | -42% |
| 3% | -42% |
| 4% | -41% |
| 5% | -40% |
Want more companies with a valuation profile/forecast similar to that of Johnson & Johnson? See ENDP, GSK, PDEX, ZTS, and REGN.
Loading social stream, please wait...